New frontiers in the diagnosis and treatment of arterial hypertension
Keywords:
arterial hypertension, evaluation, treatmentAbstract
Essential Arterial Hypertension (AH) is the most important modifiable risk factor. It should be noted that with the aging of the population, AH is increasingly prevalent, especially the form of isolated systolic arterial hypertension and its repercussions on the coronary circulation. In the last 5 decades, there has been an enormous advance in both the diagnostic and pharmacological areas. Paradoxically, these advances did not translate into greater control of Arterial Hypertension (AH) nor into the identification of curable secondary causes. This review aims in addition to bringing well-established pathophysiological concepts. Review the main methods used in the area of diagnosis for secondary AH. Emphasize the importance of clinical and laboratory assessment of complications related to AH. Discuss the new pressure goals of pharmacological treatment and emphasize, within the huge range of antihypertensive drugs, a more adequate orientation and therapeutic decision.
References
Oigman W. Hemodynamic bases of arterial hypertension. Arq Bras Cardiol. 1987;49(5):303-8.
Oigman W; Neves MF. Hipertensão arterial sistólica isolada. Revista Brasileira de Medicina (Rio de Janeiro). 2002;63: .447 - 454.
Sytkowski PA, D’Agostino RB, Belanger AJ, Kannel WB. Secular trends in long-term sustained hypertension, long-term treatment, and cardiovascular mortality. The Framingham Heart Study 1950 to 1990. Circulation 1996;93(4): 697–703.
International Society of Hypertension global hypertension practice guidelines www.jhypertension.com Volume 38 Number 6 June 2020. DOI:10.1097/HJH.0000000000002453.
ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults: Executive Summary A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Hypertension. 2018; 71:1269-1324. doi: 10.1161/HYP.0000000000000066.
Diretrizes Brasileiras de Hipertensão Arterial – 2020. Arq Bras Cardiol: doi: org/10.36660/abc.20201238
Mancia G. Clinical significance of white-coat hypertension. J Hypertens. 2016;34(4):623–6.
Grossman E, Messerli FH. Drug-induced hypertension: an unappreciated cause of secondary hypertension. Am J Med. 2012;125(1):14-22.
Law MR, Wald NJ, Morris JK, Jordan RE. Value of low dose combination treatment with blood pressure lowering drugs: analysis of 354 randomised trials. BMJ. 2003;326(7404):1427.
Julius S. Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE Randomised Trial. Lancet 2004 Jun 19;363(9426):2022-31. doi: 10.1016/S0140-6736(04)16451-9.
Wright JT Jr, Williamson JD, Whelton PK, Snyder JK, Sink KM, Rocco MV, Reboussin DM, Rahman M, Oparil S, Lewis CE, Kimmel PL, Johnson KC, Goff DC Jr, Fine LJ, Cutler JA, Cushman WC, Cheung AK, Ambrosius WT. A Randomized Trial of Intensive versus Standard Blood-Pressure Control. SPRINT Research Group,.N Engl J Med. 2015 Nov 26;373(22):2103-16. doi: 10.1056/NEJMoa1511939.
Hansson L, Zanchetti A, Carruthers SG, et al, for the HOT Study Group. Effects of intensive blood-pressure lowering and low dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial. Lancet 1998; 351: 1755–62. https://doi.org/10.1016/S0140-6736(05)79283-7Staessen JA, Fagard R, Thijs L, Celis H, Arabidze GG, Birkenhäger WH, et al. Randomised double-blind comparison of placebo and active treatment for older patients with isolated systolic hypertension. The Systolic Hypertension in Europe (Syst-Eur) Trial Investigators. Lancet. 1997;350(9080):757-64
Dahlof B, Devereux R, Kjeldsen S, Julius S, Beevers G, de Faire U, et al. Cardiovascular morbidity and mortality in the losartan intervention or endpoint reduction in hypertension study (LIFE): a randomized trial against atenolol. Lancet. 2002;359(9311):995-1003.
Beckett NS. Treatment of Hypertension in Patients 80 Years of Age or Older. N Engl J Med 2008; 358:1887-1898 doi: 10.1056/NEJMoa0801369.
Sleight P, Redon J, Verdecchia P, Mancia G, Gao P, Fagard R, et al. ONTARGET investigators. Prognostic value of blood pressure in patients with high vascular risk in the Ongoing Telmisartan Alone and in combination with Ramipril Global Endpoint Trial study. J Hypertens. 2009;27(7):1360-9.
Oigman W, Cordeiro HA, Benchimol AB, Quadra AA. Abandoment of treatment in arterial hypertension]. Arq Bras Cardiol. 1977;30(4):247-53.
